Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

NCT06340334 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT06340334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2024
Completion date
September 10, 2025
Enrollment
400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

furazolidone, helicobacter pylori infection, tegoprazan